|
NR2C1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66844316140669E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.1649995391756E-10 |
| Normal-vs-Stage2 |
1.70879976835181E-11 |
| Normal-vs-Stage3 |
2.06057393370429E-13 |
| Normal-vs-Stage4 |
5.90572035719106E-12 |
| Stage1-vs-Stage2 |
4.132300E-02 |
| Stage1-vs-Stage3 |
1.456220E-02 |
| Stage1-vs-Stage4 |
3.036000E-02 |
| Stage2-vs-Stage3 |
8.818800E-01 |
| Stage2-vs-Stage4 |
6.690600E-01 |
| Stage3-vs-Stage4 |
7.717000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.32400773572772E-13 |
| Normal-vs-AfricanAmerican |
2.459800E-03 |
| Normal-vs-Asian |
2.77859999997521E-06 |
| Caucasian-vs-AfricanAmerican |
6.468400E-01 |
| Caucasian-vs-Asian |
1.653950E-01 |
| AfricanAmerican-vs-Asian |
7.697800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.11979994563438E-09 |
| Normal-vs-Female |
1.63336011382853E-12 |
| Male-vs-Female |
2.056000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.49450452013866E-11 |
| Normal-vs-Age(41-60Yrs) |
6.01969585289908E-11 |
| Normal-vs-Age(61-80Yrs) |
6.91591228729749E-12 |
| Normal-vs-Age(81-100Yrs) |
2.10739999999543E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.196400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.999600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.546550E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.863800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.325200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.196000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.29410000002406E-07 |
| Classical-VS-Follicular |
5.220200E-01 |
| Classical-VS-Other |
5.762600E-01 |
| Classical-VS-Normal |
3.41648931367899E-12 |
| Tall-VS-Follicular |
1.964220E-03 |
| Tall-VS-Other |
9.946200E-02 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
5.446200E-01 |
| Follicular-VS-Normal |
1.52360000171825E-08 |
| Other-VS-Normal |
3.382200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.21565038222616E-14 |
| Normal-vs-N1 |
1.08170000001628E-06 |
| N0-vs-N1 |
2.847800E-01 |
|
|
